{"entity":{"type":"insider","cik":"0001590973","url":"/insider/0001590973","json_url":"/insider/0001590973.json","name":"Flagship Ventures Fund IV-Rx, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":75,"n_filings":16,"first":"2014-02-13","last":"2022-06-01","span_basis":"filed_date"},"name_variants":[{"name":"Flagship Ventures Fund IV-Rx, L.P.","source":"filing","n_filings":16,"first_seen":"2014-02-13","last_seen":"2022-06-01"}],"transactions":[{"id":6386114,"accession":"0000899243-22-020533","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-22-020533","line_url":"/filing/0000899243-22-020533","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV General Partner LLC; Nutritional Health LTP Fund, L.P.; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV-Rx, L.P.; Nutritional Health LTP Fund General Partner LLC; AFEYAN NOUBAR; Flagship Pioneering Inc.; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund IV General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27397259.0,"shares_display":"27,397,259","price_per_share":1.46,"price_display":"1.46","price_state":"stated","total_value":39999998.14,"total_display":"39,999,998.14","total_whole":"39,999,998","shares_owned_after":13698630.0,"shares_owned_after_display":"13,698,630","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-05-27","filed_date":"2022-06-01","scope":"insider","n_lines":5},{"id":6691040,"accession":"0000899243-22-011535","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-011535","line_url":"/filing/0000899243-22-011535","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Axcella Health Inc.","issuer_ticker":"AXLA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV, L.P.; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV-Rx, L.P.","owner_display_name":"Flagship Ventures Fund IV General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6319371.0,"shares_display":"6,319,371","price_per_share":1.91,"price_display":"1.91","price_state":"stated","total_value":12069998.61,"total_display":"12,069,998.61","total_whole":"12,069,999","shares_owned_after":8600403.0,"shares_owned_after_display":"8,600,403","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-16","filed_date":"2022-03-18","scope":"insider","n_lines":3},{"id":5275511,"accession":"0000899243-21-004962","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-004962","line_url":"/filing/0000899243-21-004962","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV, L.P.; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I, L.P.; Nutritional Health LTP Fund, L.P.; Flagship Ventures Fund IV-Rx, L.P.; Nutritional Health LTP Fund General Partner LLC","owner_display_name":"Flagship Ventures Fund IV General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":130000.0,"shares_display":"130,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":1950000.0,"total_display":"1,950,000.00","total_whole":"1,950,000","shares_owned_after":4125461.0,"shares_owned_after_display":"4,125,461","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-02","filed_date":"2021-02-04","scope":"insider","n_lines":4},{"id":2857666,"accession":"0000899243-20-018150","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-018150","line_url":"/filing/0000899243-20-018150","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV-Rx, L.P.; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund IV-Rx, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4666666.0,"shares_display":"4,666,666","price_per_share":3.75,"price_display":"3.75","price_state":"stated","total_value":17499997.5,"total_display":"17,499,997.50","total_whole":"17,499,998","shares_owned_after":4079032.0,"shares_owned_after_display":"4,079,032","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-29","filed_date":"2020-07-01","scope":"insider","n_lines":4},{"id":2100821,"accession":"0000899243-20-014188","txn_seq":16,"anchor":"line-16","filing_url":"/filing/0000899243-20-014188","line_url":"/filing/0000899243-20-014188","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Moderna, Inc.","issuer_ticker":"MRNA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV, L.P.; Flagship Ventures Fund IV-Rx, L.P.","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":69.5444903476,"price_display":"69.54","price_state":"stated","total_value":34772245.1738,"total_display":"34,772,245.17","total_whole":"34,772,245","shares_owned_after":22042805.0,"shares_owned_after_display":"22,042,805","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-22","filed_date":"2020-05-26","scope":"insider","n_lines":4},{"id":2100806,"accession":"0000899243-20-014188","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000899243-20-014188","line_url":"/filing/0000899243-20-014188","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Moderna, Inc.","issuer_ticker":"MRNA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV, L.P.; Flagship Ventures Fund IV-Rx, L.P.","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":66.8940622518,"price_display":"66.89","price_state":"stated","total_value":33447031.1259,"total_display":"33,447,031.13","total_whole":"33,447,031","shares_owned_after":22603085.0,"shares_owned_after_display":"22,603,085","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-21","filed_date":"2020-05-26","scope":"insider","n_lines":12},{"id":2456042,"accession":"0000899243-20-013708","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-013708","line_url":"/filing/0000899243-20-013708","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Axcella Health Inc.","issuer_ticker":"AXLA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV, L.P.; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV General Partner LLC; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV-Rx, L.P.","owner_display_name":"Flagship Ventures Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3800000.0,"shares_display":"3,800,000","price_per_share":4.75,"price_display":"4.75","price_state":"stated","total_value":18050000.0,"total_display":"18,050,000.00","total_whole":"18,050,000","shares_owned_after":2886023.0,"shares_owned_after_display":"2,886,023","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-18","filed_date":"2020-05-20","scope":"insider","n_lines":3},{"id":7831390,"accession":"0000899243-19-028975","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000899243-19-028975","line_url":"/filing/0000899243-19-028975","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Moderna, Inc.","issuer_ticker":"MRNA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"KANIA EDWIN M JR; Flagship Ventures Fund IV, L.P.; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV-Rx, L.P.; AFEYAN NOUBAR","owner_display_name":"KANIA EDWIN M JR","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":238301.0,"shares_display":"238,301","price_per_share":18.6548,"price_display":"18.65","price_state":"stated","total_value":4445457.4948,"total_display":"4,445,457.49","total_whole":"4,445,457","shares_owned_after":31216399.0,"shares_owned_after_display":"31,216,399","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-11","filed_date":"2019-12-11","scope":"insider","n_lines":2},{"id":7831384,"accession":"0000899243-19-028975","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000899243-19-028975","line_url":"/filing/0000899243-19-028975","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Moderna, Inc.","issuer_ticker":"MRNA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"KANIA EDWIN M JR; Flagship Ventures Fund IV, L.P.; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV-Rx, L.P.; AFEYAN NOUBAR","owner_display_name":"KANIA EDWIN M JR","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25417.0,"shares_display":"25,417","price_per_share":18.9586,"price_display":"18.96","price_state":"stated","total_value":481870.7362,"total_display":"481,870.74","total_whole":"481,871","shares_owned_after":31416334.0,"shares_owned_after_display":"31,416,334","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-10","filed_date":"2019-12-11","scope":"insider","n_lines":2},{"id":7831377,"accession":"0000899243-19-028975","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-19-028975","line_url":"/filing/0000899243-19-028975","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Moderna, Inc.","issuer_ticker":"MRNA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"KANIA EDWIN M JR; Flagship Ventures Fund IV, L.P.; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV-Rx, L.P.; AFEYAN NOUBAR","owner_display_name":"KANIA EDWIN M JR","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":172137.0,"shares_display":"172,137","price_per_share":18.994216099966888,"price_display":"18.99","price_state":"stated","total_value":3269607.3768,"total_display":"3,269,607.38","total_whole":"3,269,607","shares_owned_after":31437659.0,"shares_owned_after_display":"31,437,659","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-09","filed_date":"2019-12-11","scope":"insider","n_lines":2},{"id":8667371,"accession":"0001104659-19-029735","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001104659-19-029735","line_url":"/filing/0001104659-19-029735#line-12","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Axcella Health Inc.","issuer_ticker":"AXLA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV-Rx, L.P.; Flagship Ventures Opportunities Fund I, L.P.; AFEYAN NOUBAR; Flagship Ventures Fund 2007, L.P.; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures 2007 General Partner LLC; Flagship Ventures Fund IV, L.P.; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship VentureLabs IV, LLC; KANIA EDWIN M JR","owner_display_name":"Flagship Ventures Fund IV-Rx, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":986023.0,"shares_owned_after_display":"986,023","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-15","scope":"insider"},{"id":6216831,"accession":"0000899243-18-013014","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-013014","line_url":"/filing/0000899243-18-013014#line-2","is_derivative":false,"issuer_cik":"0001503559","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001503559","owner_cik":null,"owner_name":"Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV-Rx, L.P.; Flagship VentureLabs IV, LLC; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund IV General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":281250.0,"shares_display":"281,250","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4500000.0,"total_display":"4,500,000.00","total_whole":"4,500,000","shares_owned_after":18233403.0,"shares_owned_after_display":"18,233,403","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-11","filed_date":"2018-05-15","scope":"insider"},{"id":2163644,"accession":"0001012975-16-001507","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001012975-16-001507","line_url":"/filing/0001012975-16-001507","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Eleven Biotherapeutics, Inc.","issuer_ticker":"EBIO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund 2007, L.P.; AFEYAN NOUBAR; KANIA EDWIN M JR; Flagship Ventures 2007 General Partner LLC; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV-Rx, L.P.; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund 2007, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67071.0,"shares_display":"67,071","price_per_share":3.1139553607371293,"price_display":"3.11","price_state":"stated","total_value":208856.1,"total_display":"208,856.10","total_whole":"208,856","shares_owned_after":426885.0,"shares_owned_after_display":"426,885","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-23","filed_date":"2016-09-26","scope":"insider","n_lines":4},{"id":2163624,"accession":"0001012975-16-001507","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001012975-16-001507","line_url":"/filing/0001012975-16-001507#line-4","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Eleven Biotherapeutics, Inc.","issuer_ticker":"EBIO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund 2007, L.P.; AFEYAN NOUBAR; KANIA EDWIN M JR; Flagship Ventures 2007 General Partner LLC; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV-Rx, L.P.; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund 2007, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":188367.0,"shares_display":"188,367","price_per_share":3.17,"price_display":"3.17","price_state":"stated","total_value":597123.39,"total_display":"597,123.39","total_whole":"597,123","shares_owned_after":480545.0,"shares_owned_after_display":"480,545","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-22","filed_date":"2016-09-26","scope":"insider"},{"id":2163620,"accession":"0001012975-16-001507","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-16-001507","line_url":"/filing/0001012975-16-001507#line-3","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Eleven Biotherapeutics, Inc.","issuer_ticker":"EBIO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund 2007, L.P.; AFEYAN NOUBAR; KANIA EDWIN M JR; Flagship Ventures 2007 General Partner LLC; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV-Rx, L.P.; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund 2007, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":112731.0,"shares_display":"112,731","price_per_share":3.18,"price_display":"3.18","price_state":"stated","total_value":358484.58,"total_display":"358,484.58","total_whole":"358,485","shares_owned_after":668912.0,"shares_owned_after_display":"668,912","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-22","filed_date":"2016-09-26","scope":"insider"},{"id":2163617,"accession":"0001012975-16-001507","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-16-001507","line_url":"/filing/0001012975-16-001507#line-2","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Eleven Biotherapeutics, Inc.","issuer_ticker":"EBIO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund 2007, L.P.; AFEYAN NOUBAR; KANIA EDWIN M JR; Flagship Ventures 2007 General Partner LLC; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV-Rx, L.P.; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund 2007, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":47090.0,"shares_display":"47,090","price_per_share":3.17,"price_display":"3.17","price_state":"stated","total_value":149275.3,"total_display":"149,275.30","total_whole":"149,275","shares_owned_after":120198.0,"shares_owned_after_display":"120,198","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-22","filed_date":"2016-09-26","scope":"insider"}],"collapsed":true,"next_cursor":"2016-09-22|2163617","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001694665","name":"Evelo Biosciences, Inc.","url":"/issuer/0001694665","role":"Ten percent owner","n_filings":4,"first_seen":"2018-05-15","last_seen":"2022-06-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001633070","name":"Axcella Health Inc.","url":"/issuer/0001633070","role":"Ten percent owner","n_filings":3,"first_seen":"2019-05-15","last_seen":"2022-03-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001682852","name":"Moderna, Inc.","url":"/issuer/0001682852","role":"Ten percent owner","n_filings":2,"first_seen":"2019-12-11","last_seen":"2020-05-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001485003","name":"Eleven Biotherapeutics, Inc.","url":"/issuer/0001485003","role":"Ten percent owner","n_filings":5,"first_seen":"2014-02-13","last_seen":"2016-09-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001556263","name":"Syros Pharmaceuticals, Inc.","url":"/issuer/0001556263","role":"Ten percent owner","n_filings":1,"first_seen":"2016-07-07","last_seen":"2016-07-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001609809","name":"Seres Therapeutics, Inc.","url":"/issuer/0001609809","role":"Ten percent owner","n_filings":1,"first_seen":"2016-05-27","last_seen":"2016-05-27"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001590973","retrieved_at":"2026-08-27T15:41:49+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}